<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of th...

    Nymox Pharmaceutical Corporation specializes in...

    Filing Type:    PU
    Viveve Medical, Inc.

    Viveve Medical, Inc.

    Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's in...

    Viveve, Inc., the wholly owned subsidiary of Vi...

    Filing Type:    PU
    Unlimited Tomorrow, Inc.

    Unlimited Tomorrow, Inc.

    Unlimited Tomorrow is here to change the way we think about artificial limbs. They...

    Unlimited Tomorrow is here to change the way we...

    Amount Raised:    $883,964.00
    Fundraising Status:    EC
    Filing Type:    CF
    Rocket Pharmaceuticals, Inc.

    Rocket Pharmaceuticals, Inc.

    Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...

    Rocket Pharmaceuticals, Inc. is an emerging, cl...

    Filing Type:    PU
    Cyclerion Therapeutics, Inc.

    Cyclerion Therapeutics, Inc.

    Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...

    Cyclerion Therapeutics is a clinical-stage biop...

    Filing Type:    PU
    Amphastar Pharmaceuticals, Inc.

    Amphastar Pharmaceuticals, Inc.

    Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, es...

    Amphastar Pharmaceuticals, Inc., headquartered ...

    Filing Type:    PU
    ArQule, Inc.

    ArQule, Inc.

    ArQule is a biopharmaceutical company engaged in the research and development of t...

    ArQule is a biopharmaceutical company engaged i...

    Filing Type:    PU
    MacroGenics, Inc.

    MacroGenics, Inc.

    MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...

    MacroGenics is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    Personalis, Inc.

    Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development...

    Personalis, Inc. is a growing cancer genomics c...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.